Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Immunomedics (IMMU) - moderated -- Ignore unavailable to you. Want to Upgrade?

To: idahoranch1 who wrote (38483)	1/6/2017 8:12:05 PM
From: erickerickson	1 Recommendation Recommended By EMU2 Read Replies (2) \| Respond to of 63292

Mr. Ranch: You wrote: '...watching this company and looking at the history of the lack of deals while touting a "robust and diversified pipeline" and doing horrible financings over the last 9 years...' Combining that with EMU2's question from a while ago, I'd like to take a little trip down memory lane. Who knows, perhaps someone reading this board with a boatload of shares may be influenced. It strikes me that there are several "types of dissatisfaction" that contribute to a desire for change: What to people remember about the categories below and what additions are there? I'll collect them into a single post and reference it on the intro page. I'll either collect them from public posts or people can mail them to me via SI. For the summary, I'll edit it to be "just the facts ma'am" (Oh dear, how many remember Jack Webb in Dragnet?), sans motives about why things happened etc. But feel free to inject personal opinions and speculation in the meantime. Try to keep the invective to a dull roar though ;) 1: Board members and/or advisers who have come and gone. We've had several high-profile board members sign on only to disappear without much of a trace. Ditto people who were there to help with "the next deal". Names and dates (just the year) would be welcome. This is particularly relevant to the discussion about "giving venBio, say, 2 board members" and why that receives a less-than-enthusiastic response. 2: Less than stellar deals. - UCB -- bottling - Amgen -- didn't go anywhere - ??? 3: Financing: timeframes and terms? 4: Executive compensation regardless of performance. 5: Response to the venBio proxy - Sudden focus on "increasing shareholder value" - Asking for time to search for board candidates (see 1). 6: ??? I'm betting someone out there has been "keeping a little list" for years ;).... Erick